109 results on '"Leleu, A."'
Search Results
2. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
3. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
4. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
5. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
6. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
7. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
8. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma
9. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
10. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
11. Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
12. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
13. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
14. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
15. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
16. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
17. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway
18. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
19. Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia
20. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
21. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
22. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods
23. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)
24. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor
25. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
26. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
27. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens
28. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
29. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience
30. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
31. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
32. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
33. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
34. Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcγRIIa polymorphism
35. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
36. Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two cases
37. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
38. Erratum: Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
39. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
40. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma
41. Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
42. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
43. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
44. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
45. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
46. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
47. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
48. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
49. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
50. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.